Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02598960 · ClinicalTrials.gov registry record · Phase 1
An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.
A Phase 1 study of Solid Tumors, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 295
- Enrollment target
- 20
- Study locations
NCT02598960 is a Phase 1 study of Solid Tumors that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 295 participants, roughly in line with the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target. The trial reports 20 study locations across 13 states.
The verdict
NCT02598960, a Phase 1 study of Solid Tumors, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 295 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tumor-shrinking ability of experimental medication BMS-986156, when given by itself or in combination with nivolumab in patients with solid cancers that are advanced or cancers that have spread.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG BMS-986156
Study Locations (20)
Other
- Local Institution - 0012 - Ghent
- Local Institution - Paris
- Institut Claudius Regaud - Toulouse
- Institut Gustave Roussy - Vlllejuif
- Local Institution - Bonn
- Local Institution - Freiburg im Breisgau
- Local Institution - Würzburg
New South Wales
- Liverpool Cancer Therapy Center - Liverpool
- Local Institution - Westmead
Alabama
- University Of Alabama At Birmingham - Birmingham
California
- UCSD Moores Cancer Center - La Jolla
Georgia
- Emory University - Atlanta
Ohio
- The Ohio State University - Columbus
Oregon
- Providence Portland Medical Center - Portland
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2015-10-14 |
| Est. Completion | 2019-12-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02598960
The ClinicalTrials.gov registry entry for NCT02598960 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 295 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT02598960 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, New South Wales, Alabama.
Frequently Asked Questions
What is clinical trial NCT02598960 about?
NCT02598960 is a clinical study titled "An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.". The purpose of this study is to evaluate the safety and tumor-shrinking ability of experimental medication BMS-986156, when given by itself or in combination with nivolumab in patients with solid cancers that are advanced or cancers that have spread.
What is the current status of trial NCT02598960?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 295 participants. The study started on 2015-10-14. Estimated completion is 2019-12-16.
What conditions does trial NCT02598960 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT02598960?
The interventions under investigation include: Nivolumab (DRUG), BMS-986156 (DRUG).
Who is sponsoring clinical trial NCT02598960?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02598960 being conducted?
This trial has 20 study locations across Alabama, California, Georgia, Ohio, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.